Day One Biopharmaceuticals, Inc. shares rise 4.16% intraday after positive mid-term outlook from Lonza Group.

Day One Biopharmaceuticals, Inc. rose 4.16% intraday. The company's stock price increase aligns with the positive news of Wacker Chemie expanding its biotechnology research in Munich, which focuses on the manufacture of biopharmaceuticals. This expansion indicates a significant investment in the biopharmaceutical sector, suggesting potential growth and innovation in the industry.